HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
HALOZYME THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.50+0.66 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
HALOZYME THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $1.04B | $940.33M | $867.84M | $780.29M | $699.31M | $618.59M | $570.99M | $522.62M | $482.00M | $468.82M | $447.87M | $431.79M | 62.7% | +49.1% |
| Product sales, net | $476.94M | $428.83M | $376.44M | $333.14M | $325.57M | $322.95M | $303.49M | $303.73M | $303.64M | $298.64M | $300.85M | $282.42M | 28.7% | +46.5% |
| Proprietary product sales | $209.12M | $200.14M | $194.61M | $182.34M | $170.02M | $167.71M | $166.62M | $158.39M | $149.97M | $138.13M | $130.83M | $120.06M | 12.6% | +23.0% |
| Revenues under collaborative agreements | $144.41M | $139.30M | $152.33M | $129.42M | $153.79M | $142.77M | $140.84M | $121.00M | $87.67M | $95.53M | $80.53M | $66.50M | 8.7% | -6.1% |
| Upfront license and target nomination fees | $53.75M | $18.25M | $18.47M | $220.00K | $27.22M | $27.22M | $27.00M | – | – | – | – | – | 3.2% | +97.5% |
| Product sales to partners | $51.99M | $49.19M | $48.81M | $48.32M | $54.07M | $52.40M | $50.54M | $49.47M | $52.28M | $56.63M | $54.58M | $54.84M | 3.1% | -3.9% |
| Device licensing and development revenue | $17.45M | $19.05M | $16.86M | $14.70M | $14.07M | $12.05M | $11.34M | $11.50M | $10.17M | $10.53M | $9.53M | $10.50M | 1.0% | +24.0% |
| Bulk rHuPH20 sales | – | – | – | – | – | – | – | – | – | – | – | $107.52M | – | – |
| Upfront license and target nomination fees | – | – | – | – | – | – | – | – | – | $2.00M | $2.00M | $0 | – | – |
| Event-based development and regulatory milestones and other fees | – | – | $47.00M | $39.50M | $57.50M | $58.50M | $72.50M | $80.50M | $75.50M | $83.00M | $69.00M | $46.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Halozyme Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.